GlassScriptPhysician profile
David A Rybnicek
NPI 1134480197
$7,289.34
in general payments reported to CMS, 2019-2025
33 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $606 · 2021: $878 · 2022: $1,099 · 2023: $1,287 · 2024: $1,427 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,948 · Education: $51.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,947.53 |
| Education | $51.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,042.24 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $826.93 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $567.21 | 2019-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $529.80 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $483.32 | 2020-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $378.91 | 2019-2025 | Xifaxan, Plenvu |
| Pentax of America, INC. | $334.13 | 2019-2024 | Pentax Medical, C2 Cryoballoon, C2 Cryoballoon Focal Controller |
| Pfizer INC. | $259.23 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $184.94 | 2020-2024 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $175.24 | 2024-2025 | Voquezna |
| Genzyme Corporation | $166.92 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $135.32 | 2022-2023 | Rebyota, Cimzia |
| Regeneron Healthcare Solutions, INC. | $135.13 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $134.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $106.60 | 2021-2023 | Zeposia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $96.51 | 2023-2025 | Injectafer |
| Ardelyx, INC. | $92.98 | 2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $89.65 | 2021-2022 | |
| Olympus America INC. | $72.26 | 2023-2024 | Endoclot Phs, Visiglide |
| Qol Medical, LLC | $70.69 | 2023-2025 | Sucraid, Sucraid |
| Endogastric Solutions, INC | $62.57 | 2019 | |
| Lilly USA, LLC | $54.97 | 2024-2025 | Omvoh |
| Romark Laboratories, Lc | $54.13 | 2019-2020 | |
| Celltrion USA INC. | $44.22 | 2024 | Vegzelma, Zymfentra |
| Merck Sharp & Dohme LLC | $38.15 | 2021-2022 | |
| Ucb, INC. | $27.60 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $23.55 | 2025 | Iqirvo |
| Organon LLC | $22.06 | 2024 | |
| Braintree Laboratories, INC. | $20.32 | 2023 | Sutab |
| Fresenius Kabi USA, LLC | $16.94 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.62 | 2023 | Cyltezo |
| Alfasigma USA, INC. | $15.82 | 2020 | |
| Intra-Sana Laboratories | $10.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rybnicek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.